1. A PHASE II STUDY OF LENALIDOMIDE AND RITUXIMAB (R²) COMBINATION IN PATIENTS WITH HIGH‐RISK REFRACTORY/RELAPSED DIFFUSE LARGE B‐CELL LYMPHOMA. (12th June 2019) Authors: Bouabdallah, R.; Zemmour, C.; Schiano de Collela, J.; Slama, B.; Bladé, J.; Belmecheri, N.; Coso, D.; Montes de Oca, C.; Stoppa, A.; Aurran‐Schleinitz, T.; Cournier, S.; Ivanov, V.; Mescam, L.; Blaise, D. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 433 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. JAK‐STAT PATHWAY AND EPIGENETIC REGULATORS ARE CRITICAL PLAYERS IN BI‐ALCL PATHOGENESIS?. (12th June 2019) Authors: Laurent, C.; Nicolae, A.; Laurent, C.; Le Bras, F.; Haioun, C.; Fataccioli, V.; Amara, N.; Adélaïde, J.; Guille, A.; Schiano De Colella, J.; Tesson, B.; Traverse‐Glehen, A.; Chenard, M.; Mescam, L.; Moreau, A.; Chassagne‐Clément, C.; Somja, J.; Escudié, F.; André, M.; Martin, N. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 201 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗